Welch & Forbes’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-776
| Closed | -$220K | – | 388 |
|
|
2021
Q3 | $220K | Sell |
776
-150
| -16% | -$49.2K | ﹤0.01% | 378 |
|
|
2021
Q2 | $321K | Sell |
926
-665
| -42% | -$201K | 0.01% | 343 |
|
|
2021
Q1 | $446K | Sell |
1,591
-60
| -4% | -$16.2K | 0.01% | 293 |
|
|
2020
Q4 | $404K | Hold |
1,651
| – | – | 0.01% | 300 |
|
|
2020
Q3 | $468K | Hold |
1,651
| – | – | 0.01% | 251 |
|
|
2020
Q2 | $442K | Sell |
1,651
-400
| -20% | -$120K | 0.01% | 250 |
|
|
2020
Q1 | $649K | Buy |
2,051
+5
| +0.2% | +$1.52K | 0.02% | 214 |
|
|
2019
Q4 | $607K | Sell |
2,046
-275
| -12% | -$76.3K | 0.01% | 245 |
|
|
2019
Q3 | $540K | Sell |
2,321
-260
| -10% | -$60.5K | 0.01% | 251 |
|
|
2019
Q2 | $603K | Sell |
2,581
-965
| -27% | -$223K | 0.01% | 244 |
|
|
2019
Q1 | $838K | Sell |
3,546
-3,197
| -47% | -$1.01M | 0.02% | 212 |
|
|
2018
Q4 | $2.03M | Sell |
6,743
-240
| -3% | -$76.6K | 0.06% | 162 |
|
|
2018
Q3 | $2.47M | Sell |
6,983
-957
| -12% | -$329K | 0.06% | 162 |
|
|
2018
Q2 | $2.31M | Buy |
7,940
+56
| +0.7% | +$15.7K | 0.06% | 164 |
|
|
2018
Q1 | $2.16M | Buy |
7,884
+641
| +9% | +$199K | 0.06% | 174 |
|
|
2017
Q4 | $2.31M | Sell |
7,243
-423
| -6% | -$136K | 0.06% | 158 |
|
|
2017
Q3 | $2.4M | Sell |
7,666
-233
| -3% | -$69K | 0.06% | 160 |
|
|
2017
Q2 | $2.14M | Sell |
7,899
-5,073
| -39% | -$1.34M | 0.06% | 162 |
|
|
2017
Q1 | $3.55M | Sell |
12,972
-1,376
| -10% | -$389K | 0.1% | 139 |
|
|
2016
Q4 | $4.07M | Sell |
14,348
-625
| -4% | -$185K | 0.12% | 131 |
|
|
2016
Q3 | $4.69M | Sell |
14,973
-270
| -2% | -$80K | 0.16% | 114 |
|
|
2016
Q2 | $3.69M | Buy |
15,243
+2,363
| +18% | +$623K | 0.11% | 131 |
|
|
2016
Q1 | $3.35M | Buy |
12,880
+1,794
| +16% | +$474K | 0.1% | 133 |
|
|
2015
Q4 | $3.4M | Sell |
11,086
-2,412
| -18% | -$693K | 0.11% | 131 |
|
|
2015
Q3 | $3.94M | Sell |
13,498
-720
| -5% | -$238K | 0.13% | 126 |
|
|
2015
Q2 | $5.74M | Buy |
14,218
+983
| +7% | +$395K | 0.18% | 114 |
|
|
2015
Q1 | $5.59M | Buy |
13,235
+8,121
| +159% | +$3.2M | 0.17% | 120 |
|
|
2014
Q4 | $1.74M | Sell |
5,114
-29
| -0.6% | -$9.38K | 0.05% | 176 |
|
|
2014
Q3 | $1.7M | Buy |
5,143
+147
| +3% | +$48.5K | 0.05% | 180 |
|
|
2014
Q2 | $1.58M | Buy |
4,996
+78
| +2% | +$23.5K | 0.05% | 178 |
|
|
2014
Q1 | $1.5M | Hold |
4,918
| – | – | 0.05% | 185 |
|
|
2013
Q4 | $1.38M | Sell |
4,918
-297
| -6% | -$76.8K | 0.04% | 181 |
|
|
2013
Q3 | $1.25M | Buy |
5,215
+1,315
| +34% | +$294K | 0.04% | 184 |
|
|
2013
Q2 | $840K | Buy |
+3,900
| New | +$833K | 0.03% | 201 |
|
Other funds holding BIIB
Welch & Forbes's BIIB Position: Q4 2021 in Review
Welch & Forbes sold out of Biogen (BIIB) in Q4 2021, closing a stake of 776 shares — an estimated $220K sold.
Welch & Forbes first reported a position in BIIB in Q2 2013 and held it in 34 quarters. The position peaked at $5.74M in Q2 2015. 1,010 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.
- Welch & Forbes reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
- Welch & Forbes sold 776 Biogen shares in Q4 2021, an estimated $220K.
- Welch & Forbes first reported a position in Biogen in Q2 2013 and held it in 34 quarters.
- Welch & Forbes's Biogen position peaked at $5.74M in Q2 2015.
- 1,010 funds tracked by Wall St. Rank held Biogen as of Q4 2021.
Based on Welch & Forbes's 13F filing for Q4 2021, filed 19 Jan 2022.